Erschienen in:
01.04.2003 | Short Communication
Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever
verfasst von:
Satheesh K. Kathula, Ketan Shah, Hari Polenakovik, Jhansi Koduri
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 4/2003
Einloggen, um Zugang zu erhalten
Abstract
Neoplastic fever is relatively common in cancer patients. Naproxen is one of the most commonly used non-steroidal anti-inflammatory drugs for the treatment of neoplastic fever. Naproxen is associated with platelet dysfunction and gastrointestinal side effects. We substituted rofecoxib, a cyclooxygenase-II inhibitor, for naproxen in patients with a previous history of, or a newly diagnosed, neoplastic fever in whom naproxen was relatively contraindicated. In all patients the fever resolved completely without any side effects.